Literature DB >> 31523357

Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Aryan Rafiee Zadeh1, Mozhde Askari1, Niloufar Nasr Azadani2, Akram Ataei3, Keyvan Ghadimi1, Nooshin Tavoosi4, Masih Falahatian1.   

Abstract

Multiple Sclerosis (MS) is chronic, inflammatory, a neurologic disorder of the central nervous system (CNS). Although the exact mechanisms of MS have not been yet discovered some drugs are found helpful for its treatment. These drugs which are divided into the first line, second line and third-line therapies, have demonstrated to be helpful for MS patients based on immune basic of the disease. Previous studies have been indicated that deterioration of MS condition is associated with a stronger immune system. Most of these therapies impact on the immune system and immune cells including shifting immune cell populations toward a Th2 dominant population or suppression of the immune system so that auto-reactive immune cells cannot attack myelin sheath of neurons. Beside many beneficial effects of these drugs, some adverse effects (AE) have been reported in many experiments and clinical trials among patients suffering from MS. In this review, we conclude some AEs of beta interferon, mitoxantrone, natalizumab and fingolimod, reported in different papers and we continue the rest of the drugs in second part of our review article.

Entities:  

Keywords:  Mechanism; adverse effect; drug; multiple sclerosis

Year:  2019        PMID: 31523357      PMCID: PMC6737429     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  68 in total

1.  Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Authors:  R G Ghalie; G Edan; M Laurent; E Mauch; S Eisenman; H P Hartung; R E Gonsette; M D Butine; D E Goodkin
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

2.  PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

Authors: 
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

3.  Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

Authors:  H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

4.  Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

Authors:  Jagannadha R Avasarala; Anne H Cross; David B Clifford; Barry A Singer; Barry A Siegel; Elliot E Abbey
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

5.  Multiple sclerosis, interferon beta-1b and depression A prospective investigation.

Authors:  Anthony Feinstein; Paul O'Connor; Karen Feinstein
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849

6.  Therapy-related acute promyelocytic leukemia.

Authors:  M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

7.  Natalizumab for active Crohn's disease.

Authors:  Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

Review 8.  A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Authors:  R G Ghalie; E Mauch; G Edan; H P Hartung; R E Gonsette; S Eisenmann; E Le Page; M D Butine; D E De Goodkin
Journal:  Mult Scler       Date:  2002-10       Impact factor: 6.312

9.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

View more
  20 in total

1.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

2.  Urinary incontinency after radical prostatectomy and effects of 1 month pre-operative biofeedback training.

Authors:  Hossein Abdollahi Veshnavei
Journal:  Am J Clin Exp Urol       Date:  2021-12-15

3.  Evaluation of patterns, cause and risk factors of burns in patients with seizure.

Authors:  Seyyed Mahdi Zia Ziabari; Mohammad Reza Mobayen; Sheyda Rimaz; Daniel Rahimi Nejat; Siamak Rimaz
Journal:  Int J Burns Trauma       Date:  2022-02-15

4.  Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women.

Authors:  Hossein Abdollahi Veshnavei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-02-15

5.  Platelet-rich plasma therapy or arthroscopic surgery on repair of anterior cruciate ligament rupture.

Authors:  Sepehr Eslami; Shamim Fattah; Soosan Alimohammadzade Taher; Zahra Rezasoltani
Journal:  Eur J Transl Myol       Date:  2022-08-01

6.  Predictive value of number and volume of demyelinating plaques in treatment response in patients with multiple sclerosis treated with INF-B.

Authors:  Maryam Azizian; Nadia Ghasemi Darestani; Athena Aliabadi; Mahdieh Afzali; Nooshin Tavoosi; Mahnaz Fosouli; Jalil Khataei; Halimeh Aali; Sayed Mohammad Amin Nourian
Journal:  Am J Neurodegener Dis       Date:  2022-04-15

Review 7.  The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.

Authors:  Ting Yang; Xin Tian; Chao-Yang Chen; Ling-Yun Ma; Shuang Zhou; Min Li; Ye Wu; Ying Zhou; Yi-Min Cui
Journal:  Br J Clin Pharmacol       Date:  2020-02-08       Impact factor: 4.335

8.  Evaluation of proximal femoral geometry and its relationship with body mass index in Iranian people: a cross sectional study.

Authors:  Masoumeh Faghani; Payman Asadi; Seyyed Mahdi Zia Ziabari; Nazanin Noori Roodsari; Esmaiel Nourisa; Amirali Daryagasht
Journal:  Int J Burns Trauma       Date:  2021-12-15

9.  Evaluation of the efficacy of Agicoat in the treatment of partial-thickness skin graft donor sites of burn patients.

Authors:  Hossein Abdollahi Veshnavei
Journal:  Int J Burns Trauma       Date:  2021-12-15

10.  The relationship between menstrual disorders and education in women with intractable epilepsy.

Authors:  Mahdieh Afzali; Jafar Mehvari Habibabadi; Banafsheh Mohammadi; Sanaz Masoumi; Mahta Ranjbar; Masoumeh Cheshmavar; Seyed Navid Naghibi
Journal:  Am J Neurodegener Dis       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.